Preference of acromegaly patients for treatment attributes in Spain

被引:0
|
作者
Fajardo, Carmen [1 ]
Alvarez-Escola, Cristina [2 ]
Biagetti, Betina [3 ,4 ]
Garcia-Centeno, Rogelio [5 ]
Ciriza, Raquel [6 ]
Sanchez-Cenizo, Laura [7 ]
Diaz-Munoz, Marcos [7 ]
机构
[1] Ribera Univ Hosp, Endocrinol Dept, Alzira, Valencia, Spain
[2] La Paz Univ Hosp, Endocrinol Dept, Madrid, Spain
[3] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Diabet & Metab Res Unit, Barcelona, Spain
[4] Univ Autonoma Barcelona, Vall Hebron Res Inst VHIR, Barcelona, Spain
[5] Gregorio Maranon Univ Hosp, Endocrinol Dept, Madrid, Spain
[6] Spanish Assoc People Affected Acromegaly Asociac P, Huesca, Spain
[7] Pfizer SLU, Med Affairs Dept, Alcobendas, Madrid, Spain
关键词
Acromegaly; Growth hormone; Quality of life; Treatment; Preferences; QUALITY-OF-LIFE; DIAGNOSIS; DISEASE; QUESTIONNAIRE; PERCEPTIONS; PEGVISOMANT; PASIREOTIDE; EXPERIENCE; MANAGEMENT; PITUITARY;
D O I
10.1007/s12020-023-03462-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveAcromegaly is a rare disease caused by increased growth hormone secretion and a subsequent increase in insulin-like growth factor I (IGF-I) levels. Patients display multiple comorbidities that affect their quality of life (QoL). Treatment aims to maintain good biochemical control, tumour control and reduce the risk of comorbidities; however, their impact on QoL has been overlooked until recently. We interviewed patients to explore their preferences with regard to treatment attributes.DesignA cross-sectional study based on interviews and a discrete choice experiment (DCE) in a Spanish cohort.MethodsAdult patients diagnosed with acromegaly & GE;1 year before the start of the study and under treatment were included. Treatment attributes were collected from patient testimony during face-to-face interviews. Then, a DCE was performed to elicit patient preferences for certain treatment attributes.ResultsSixty-seven patients completed the study. QoL improvement was the most important treatment attribute (37%), followed by IGF-I control (20%), blood sugar control (17%) and tumour control (13%). Secondary attributes were pain associated with the route of administration (7%), diarrhoea (2%), administration method (2%) and storage conditions (2%). We then calculated the theoretical share of preference for existing treatments, based on the individual preference utility for each attribute and level. Pegvisomant obtained the highest share of preference overall, and the highest preference as a second-line treatment (53 and 95%, respectively).ConclusionsQoL greatly influences patient treatment preference. Since acromegaly patients are informed and aware of their disease, treatment choices should always be shared with patients.
引用
收藏
页码:379 / 389
页数:11
相关论文
共 50 条
  • [21] Patterns of pharmacologic treatment in US patients with acromegaly
    Broder, Michael S.
    Chang, Eunice
    Ludlam, William H.
    Neary, Maureen P.
    Carmichael, John D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (05) : 799 - 805
  • [22] THE RESULT OF SURGICAL AND COMBINED TREATMENT OF PATIENTS WITH ACROMEGALY
    Ibrahim, Sameh R. A.
    Chmutin, Gennady
    Koval, K., V
    Mekhaeel, M. Sh
    Wajdy, Al Awaida
    Al-bawareed, O. A.
    PHARMACOPHORE, 2020, 11 (05): : 72 - 76
  • [23] Emphasis on the significance of octreotide treatment in patients with acromegaly
    Stalldecker, Graciela
    SALUD I CIENCIA, 2007, 15 (05): : 874 - 874
  • [24] Treatment outcomes and mortality of 94 patients with acromegaly
    R. Trepp
    C. Stettler
    M. Zwahlen
    R. Seiler
    P. Diem
    E. R. Christ
    Acta Neurochirurgica, 2005, 147 : 243 - 251
  • [25] Preoperative Medical Treatment for Patients With Acromegaly: Yes or No
    Albarel, Frederique
    Cuny, Thomas
    Graillon, Thomas
    Dufour, Henry
    Brue, Thierry
    Castinetti, Frederic
    JOURNAL OF THE ENDOCRINE SOCIETY, 2022, 6 (09)
  • [26] Voice Characteristics in Patients with Acromegaly during Treatment
    Wolters, Thalijn L. C.
    Roerink, Sean H. P. P.
    Drenthen, Linda C. A.
    Wagenmakers, Margaretha A. E. M.
    van den Broek, Guido B.
    Rutten, Kim I. M.
    Herruer, Jasmijn M.
    Hermus, Adrianus R. M. M.
    Netea-Maier, Romana T.
    JOURNAL OF VOICE, 2021, 35 (06) : 932.e13 - 932.e27
  • [27] Preference Based Valuation of Treatment Attributes in Haemophilia A Using Web Survey
    Carlsson, K. Steen
    Andersson, E.
    Berntorp, E.
    HAEMOPHILIA, 2017, 23 : 92 - 92
  • [28] DEVELOPING TREATMENT ATTRIBUTES FOR A PATIENT PREFERENCE SURVEY IN INFLAMMATORY BOWEL DISEASE
    Schoefs, E.
    Vermeire, S.
    Ferrante, M.
    Sabino, J.
    Verstockt, B.
    Avedano, L.
    Haaf, I
    De Rocchis, M. S.
    Broggi, A.
    Sajak-Szczerba, M.
    Saldana, R.
    Huys, I
    Janssens, R.
    VALUE IN HEALTH, 2022, 25 (12) : S434 - S434
  • [29] Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
    Pedro de Pablos-Velasco
    Eva María Venegas
    Cristina Álvarez Escolá
    Carmen Fajardo
    Paz de Miguel
    Natividad González
    Ignacio Bernabéu
    Nuria Valdés
    Miguel Paja
    Juan José Díez
    Betina Biagetti
    Pituitary, 2020, 23 : 129 - 139
  • [30] Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
    de Pablos-Velasco, Pedro
    Maria Venegas, Eva
    Alvarez Escola, Cristina
    Fajardo, Carmen
    de Miguel, Paz
    Gonzalez, Natividad
    Bernabeu, Ignacio
    Valdes, Nuria
    Paja, Miguel
    Jose Diez, Juan
    Biagetti, Betina
    PITUITARY, 2020, 23 (02) : 129 - 139